OPIOID-FREE ANALGESIA IN ICU IN INTENSIVE CARE UNIT - Trial NCT05825560
Access comprehensive clinical trial information for NCT05825560 through Pure Global AI's free database. This Phase 4 trial is sponsored by Centre Hospitalier Universitaire de Nฤซmes and is currently Not yet recruiting. The study focuses on Intubation. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Centre Hospitalier Universitaire de Nฤซmes
Timeline & Enrollment
Phase 4
Jun 01, 2023
Apr 01, 2025
Primary Outcome
Daily remifentanil consumption (after randomisation)
Summary
ICU patients experience moderate to severe pain. Studies and guidelines point out the
 benefits of multimodal analgesia on pain control, opioid spare and on lowering its adverse
 effects. However, no recommendation about drugs or protocol has been formulated. In our
 study, we studied the feasibility and the impact on Remifentanil spare of a standardized
 protocol using multimodal analgesia (Paracetamol, Nefopam, Tramadol, Ketamine, Remifentanil)
 compared to the standard-of-care strategy using Paracetamol and Remifentanil. We conducted a
 prospective, ''proof of concept'', randomized, double-blind, parallel group,
 placebo-controlled trial. We studied multimodal analgesia versus standard-of-care in ICU
 patients requiring sedation-analgesia for invasive mechanical ventilation.We hypothesized
 that Remifentanil consumption decrease by 15% with the use of a standardized multimodal
 analgesia strategy
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05825560
Non-Device Trial